NoRD Bio — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

NoRD Bio is a private, pre-revenue biotech founded in 2020, based in San Diego, CA. The company has developed the SmartRD Platform, a proprietary liquid biopsy and computational platform designed for ultra-deep, multi-omic analysis of cell-free DNA to monitor cancer progression, evolution, and resistance with high sensitivity. Led by a scientifically distinguished team with roots at the Broad Institute, Harvard, and Dana-Farber, NoRD Bio is positioned to address critical gaps in cancer monitoring and biomarker discovery, though it faces significant competition and the challenge of translating its advanced technology into clinical adoption and revenue.

Oncology

Technology Platform

SmartRD Platform: An integrated liquid biopsy system combining ultra-deep cfDNA sequencing, comprehensive epigenetic (methylation/nucleosome) profiling, and a proprietary AI/ML computational engine for advanced cancer monitoring and biomarker discovery.

Opportunities

The rapidly expanding liquid biopsy market, particularly for minimal residual disease (MRD) detection and therapy monitoring, presents a multi-billion dollar opportunity.

NoRD Bio's multi-omic, AI-enhanced platform is well-positioned to serve the high-complexity needs of pharmaceutical companies for biomarker discovery and clinical trial support, a high-value niche.

Risk Factors

The company faces intense competition from well-capitalized public and private liquid biopsy firms.

A key risk is the long and costly path to clinical validation, regulatory approval, and demonstrating reimbursement-worthy utility for its advanced platform.

Execution risk in scaling from research to a commercial product is also significant.

Competitive Landscape

NoRD Bio competes in the crowded liquid biopsy market against dominant players like Guardant Health and Exact Sciences, which have established commercial tests and sales networks. It also competes with other multi-omic and MRD-focused companies such as Natera, Freenome, and Personalis. Its differentiation hinges on the combined depth of sequencing, unique epigenetic data layer, and proprietary AI analysis.

More companies in United States →